Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, was evaluated in patients with chronic kidney disease (CKD) and type 2 diabetes to assess its long-term effects on kidney and cardiovascular outcomes. In this double-blind trial, 5734 patients were randomized to receive finerenone or placebo. The primary composite outcome (kidney failure, sustained decrease in eGFR ≥40%, or renal death) occurred in 17.8% of the finerenone group versus 21.1% in the placebo group (hazard ratio, 0.82; 95% CI, 0.73–0.93; P=0.001). The key secondary outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure hospitalization) was also reduced with finerenone (13.0% vs. 14.8%; hazard ratio, 0.86; 95% CI, 0.75–0.99; P=0.03). Hyperkalemia-related discontinuation was higher with finerenone (2.3% vs. 0.9%). The study concluded that finerenone reduces risks of CKD progression and cardiovascular events in this patient population.

Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, was evaluated in patients with chronic kidney disease (CKD) and type 2 diabetes to assess its long-term effects on kidney and cardiovascular outcomes. In this double-blind trial, 5734 patients were randomized to receive finerenone or placebo. The primary composite outcome (kidney failure, sustained decrease in eGFR ≥40%, or renal death) occurred in 17.8% of the finerenone group versus 21.1% in the placebo group (hazard ratio, 0.82; 95% CI, 0.73–0.93; P=0.001). The key secondary outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure hospitalization) was also reduced with finerenone (13.0% vs. 14.8%; hazard ratio, 0.86; 95% CI, 0.75–0.99; P=0.03). Hyperkalemia-related discontinuation was higher with finerenone (2.3% vs. 0.9%). The study concluded that finerenone reduces risks of CKD progression and cardiovascular events in this patient population.